Showing 3781-3790 of 8905 results for "".
- Research Shows Skin Can Reflect Eating Habitshttps://practicaldermatology.com/news/research-shows-skin-can-reflect-eating-habits/2458822/Dermatologists at Baylor College of Medicine say there is evidence that links certain foods to flares in acne. “While there are definitely a number of triggers for acne, the connection between diet and acne is very interesting,” said Dr. Rajani Katta, professor of dermatology
- Chromogenex Releases Regenlite Transformhttps://practicaldermatology.com/news/chromogenex-releases-regenlite-transform/2459042/The latest addition to the Chromogenex family, Regenlite Transform is now available. It is specifically designed for managing inflammatory skin conditions without any discomfort, downtime or residual cell necrosis, the company says. A pure 585nm laser offers 300% more absorption in Oxyhae
- Late Stage Skin Cancers on the Rise in the UK: World Congress on Cancers of the Skinhttps://practicaldermatology.com/news/20140917-late_stage_skin_cancers_on_the_rise_in_the_uk_world_congress_on_cancers_of_the_skin/2459119/Advanced-stage skin cancers are on the rise in the UK, according to two studies presented this month at the World Congress on Cancers of the Skin in Edinburgh, Scotland. The findings highlight an urgent need to publicise self-check and early detection messages, the The Skin Cancer Foundation says.
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- Speech Recognition Software Gets Boosthttps://practicaldermatology.com/news/20130828-speech_recognition_software_gets_boost/2459473/Spellex has released Spellex Dictation, a dictionary enhancement for Dragon NaturallySpeaking and other popular speech recognition software. Spellex says the dictation program allows users to dictate and correctly spell healthcare, legal, and BioScientific and engineering words and phrases.
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- SENTE Launches Collaborations with Galderma, The HydraFacial Companyhttps://practicaldermatology.com/news/sente-launches-collaborations-with-galderma-the-hydrafacial-company/2457546/New strategic collaborations are intended to broaden the reach of SENTÉ and further expand their disruptive professional grade skin care product portfolio, the company says. Both collaborations will offer consumers the opportunity
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Awardhttps://practicaldermatology.com/news/zoryve-wins-2025-allure-best-of-beauty-breakthrough-award/2483410/Arcutis Biotherapeutics’ ZORYVE® (roflumilast) was the recipient of Allure magazine’s 2025 Best of Beauty Breakthrough Award, marking the first time a prescription topical for atopic dermatitis (AD), plaque psoriasis, and seborrheic dermatitis has received the accol